Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system

Published:2023-07 Issue:7 Volume:23 Page:806-815
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Lewnard Joseph A,McLaughlin John M,Malden Debbie,Hong Vennis,Puzniak Laura,Ackerson Bradley K,Lewin Bruno J,Kim Jeniffer S,Shaw Sally F,Takhar Harpreet,Jodar Luis,Tartof Sara Y

Funder

National Institutes of Health

Centers for Disease Control and Prevention

National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference25 articles.

1. Antibody evasion properties of SARS-CoV-2 omicron sublineages;Iketani;Nature,2022

2. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;N Engl J Med,2022

3. Nirmatrelvir use and severe COVID-19 outcomes during the omicron surge;Arbel;N Engl J Med,2022

4. Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system;Dryden-Peterson;medRxiv,2022

5. Effectiveness of Paxlovid in reducing severe COVID-19 and mortality in high-risk patients;Najjar-Debbiny;Clin Infect Dis,2022

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia;BMC Infectious Diseases;2024-08-05

2. Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions;Infectious Diseases and Therapy;2024-08-03

3. Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan;Journal of Infection and Chemotherapy;2024-08

4. US Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients;Current Therapeutic Research;2024-08

5. In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance;Science Advances;2024-07-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3